Roche defends buying lavish meals for doctors at Sydney's restaurants

Ray Moynihan

doi:10.1136/bmj.333.7560.169

Roche defends buying lavish meals for doctors at Sydney's restaurants

Ray Moynihan^*

^*Corresponding author for this work

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Article › Professional

1 Citation (Scopus)

Abstract

The dinners were part of a Roche sponsored scientific symposium on haematology-oncology treatments, which included the company's top selling pharmaceutical, rituximab (MabThera), which has annual sales of more than SFr4bn (£1.8bn; €2.6bn; $3.2bn).

Original language	English
Pages (from-to)	169-169
Number of pages	1
Journal	BMJ (Clinical research ed.)
Volume	333
Issue number	7560
DOIs	https://doi.org/10.1136/bmj.333.7560.169
Publication status	Published - 20 Jul 2006

Access to Document

10.1136/bmj.333.7560.169

Cite this

@article{5807a1b9d0b34f8d88dd65642ae4b669,

title = "Roche defends buying lavish meals for doctors at Sydney's restaurants",

abstract = "The dinners were part of a Roche sponsored scientific symposium on haematology-oncology treatments, which included the company's top selling pharmaceutical, rituximab (MabThera), which has annual sales of more than SFr4bn (£1.8bn; €2.6bn; \$3.2bn).",

author = "Ray Moynihan",

year = "2006",

month = jul,

day = "20",

doi = "10.1136/bmj.333.7560.169",

language = "English",

volume = "333",

pages = "169--169",

journal = "BMJ (Clinical research ed.)",

issn = "0959-535X",

publisher = "BMJ Publishing Group",

number = "7560",

}

TY - JOUR

T1 - Roche defends buying lavish meals for doctors at Sydney's restaurants

AU - Moynihan, Ray

PY - 2006/7/20

Y1 - 2006/7/20

N2 - The dinners were part of a Roche sponsored scientific symposium on haematology-oncology treatments, which included the company's top selling pharmaceutical, rituximab (MabThera), which has annual sales of more than SFr4bn (£1.8bn; €2.6bn; $3.2bn).

AB - The dinners were part of a Roche sponsored scientific symposium on haematology-oncology treatments, which included the company's top selling pharmaceutical, rituximab (MabThera), which has annual sales of more than SFr4bn (£1.8bn; €2.6bn; $3.2bn).

UR - https://www.scopus.com/pages/publications/33746297403

U2 - 10.1136/bmj.333.7560.169

DO - 10.1136/bmj.333.7560.169

M3 - Article

C2 - 16858041

AN - SCOPUS:33746297403

SN - 0959-535X

VL - 333

SP - 169

EP - 169

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

IS - 7560

ER -

Roche defends buying lavish meals for doctors at Sydney's restaurants

Abstract

Access to Document

Other files and links

Fingerprint

Cite this